Proteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframe.

ABSTRACT: Genomics has transformed the diagnostic landscape of pediatric malignancies by identifying and integrating actionable features that refine diagnosis, classification, and treatment. Yet, translating precision oncology data into effective therapies for hard-to-cure childhood, adolescent, and young adult malignancies remains a significant challenge. We present the case for combining proteomics with patient-derived xenograft models to identify personalized treatment for an adolescent with primary and metastatic spindle epithelial tumor with thymus-like elements (SETTLE). Within two weeks of biopsy, proteomics identified elevated SHMT2 as a target for therapy with the anti-depressant sertraline. Drug response was confirmed within two months using a personalized chicken chorioallantoic membrane

SUBMITTER: Barnabas GD 

PROVIDER: S-EPMC11982353 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature